Syros Pharmaceuticals, Inc. (30)
Browse by Contract Category
Contracts
-
Master Collaboration Agreement dated March 7, 2022 between Syros Pharmaceuticals, Inc. and QIAGEN Manchester Limited
(Filed With SEC on May 16, 2022)
-
Form of Restricted Stock Unit Agreement under 2022 Inducement Stock Incentive Plan
(Filed With SEC on March 15, 2022)
-
Description of Securities Registered under Section 12 of the Exchange Act
(Filed With SEC on March 15, 2022)
-
Form of Nonstatutory Stock Option Agreement for Inducement Awards
(Filed With SEC on October 13, 2021)
-
Amendment No. 1 to Amended and Restated Cancer License Agreement, dated January 8, 2021, by and between the Registrant and TMRC Co., Ltd
(Filed With SEC on May 6, 2021)
-
Lease Termination Agreement dated as of November 1, 2019 between Syros Pharmaceuticals, Inc. and 620 Memorial Leasehold LLC
(Filed With SEC on November 4, 2019)
-
Form of Nonstatutory Stock Option Agreement under 2022 Inducement Stock Incentive Pla
(Filed With SEC on March 15, 2022)
-
2022 Inducement Stock Incentive Plan
(Filed With SEC on March 15, 2022)
-
Offer Letter, effective September 27, 2021, between Syros Pharmaceuticals, Inc. and Conley Chee
(Filed With SEC on November 5, 2021)
-
Offer Letter, effective October 12, 2021, between Syros Pharmaceuticals, Inc. and Jason Haas
(Filed With SEC on October 13, 2021)
-
Description of Securities Registered under Section 12 of the Exchange Act
(Filed With SEC on March 4, 2021)
-
Underwriting Agreement, dated January 19, 2021, by and among Syros Pharmaceuticals, Inc., Cowen and Company, LLC and Piper Sandler & Co., as representatives of the several...
(Filed With SEC on January 20, 2021)
-
Form of Pre-Funded Warrant
(Filed With SEC on December 7, 2020)
-
Registration Rights Agreement, dated December 4, 2020, by and among Syros Pharmaceuticals, Inc. and the persons party thereto
(Filed With SEC on December 7, 2020)
-
Securities Purchase Agreement, dated December 4, 2020, by and among Syros Pharmaceuticals, Inc. and the persons party thereto
(Filed With SEC on December 7, 2020)
-
Form of Warrant to Purchase Common Stock or Pre-Funded Warrants
(Filed With SEC on December 7, 2020)
-
Asset Purchase Agreement, dated as of December 4, 2020, by and between Syros Pharmaceuticals, Inc. and Orsenix, LLC
(Filed With SEC on December 7, 2020)
-
License and Collaboration Agreement dated December 17, 2019 by and between the Registrant and Global Blood Therapeutics, Inc
(Filed With SEC on March 5, 2020)
-
Letter Agreement dated November 18, 2019 by and between the Registrant and Incyte Corporation
(Filed With SEC on March 5, 2020)
-
Offer Letter dated April 24, 2013 by and between the Registrant and Eric R. Olson, Ph.D
(Filed With SEC on March 5, 2020)
-
Description of Securities Registered under Section 12 of the Exchange Act
(Filed With SEC on March 5, 2020)
-
Loan and Security Agreement, dated February 12, 2020, by and among Syros Pharmaceuticals, Inc. and Oxford Finance LLC, as collateral agent and lender
(Filed With SEC on February 13, 2020)
-
Consulting Agreement dated August 8, 2012 between the Registrant and Richard A. Young, Ph.D., as amended
(Filed With SEC on November 12, 2019)
-
Form of Series A Convertible Preferred Stock Certificate
(Filed With SEC on April 8, 2019)
-
Form of Class A Warrant
(Filed With SEC on April 8, 2019)
-
Underwriting Agreement relating to the Preferred Offering, dated April 5, 2019, by and among Syros Pharmaceuticals, Inc., Cowen and Company, LLC and Piper Jaffray & Co., as...
(Filed With SEC on April 8, 2019)
-
Underwriting Agreement relating to the Common Offering, dated April 5, 2019, by and among Syros Pharmaceuticals, Inc., Cowen and Company, LLC and Piper Jaffray & Co., as...
(Filed With SEC on April 8, 2019)
-
Amended and Restated Cancer License Agreement dated April 28, 2016 by and between the Registrant and TMRC Co., Ltd
(Filed With SEC on March 7, 2019)
-
Form of Restricted Stock Unit Agreement under 2016 Stock Incentive Plan
(Filed With SEC on March 7, 2019)
-
Lease dated January 8, 2019 between the Company and DIV 35 CPD, LLC
(Filed With SEC on January 11, 2019)